Transgene SA 2015 IR
The report highlights Transgene's strategic restructuring in 2015, focusing on its core business of developing immunotherapy drug candidates for cancer and infectious diseases while outsourcing bio-manufacturing. This restructuring included the sale of its production assets to ABL Europe and a significant headcount reduction. Financially, the company secured a €20 million loan facility from the European Investment Bank and a €10 million commitment from Institut Mérieux. On the clinical front, Transgene achieved positive Phase 2b results for TG4010 in non-small cell lung cancer, published in The Lancet Oncology, and advanced Pexa-Vec into Phase 3 trials for liver cancer.
Company: Transgene SA
Sector: Professional & technical services
Country: France
Year: 2015
Type: IR
Pages: 172
Back to company
Transgene SA
Reference Document
The report highlights Transgene's strategic restructuring in 2015, focusing on its core business of developing immunotherapy drug candidates for cancer and infectious diseases while outsourcing bio-manufacturing. This restructuring included the sale of its production assets to ABL Europe and a significant headcount reduction. Financially, the company secured a €20 million loan facility from the European Investment Bank and a €10 million commitment from Institut Mérieux. On the clinical front, Transgene achieved positive Phase 2b results for TG4010 in non-small cell lung cancer, published in The Lancet Oncology, and advanced Pexa-Vec into Phase 3 trials for liver cancer.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Published
Apr 28, 2016
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Employees